Nuvectis Pharma shareholders elect director, ratify auditor at 2025 annual meeting

Nuvectis Pharma, Inc.

Quorum of 14,605,167 shares (61.86%) present out of 23,606,443 outstanding shares.
Class III director James Oliviero elected with 9,882,555 votes for, 240,327 against, 782 abstentions.
Ratification of Kesselman & Kesselman as independent auditor approved with 14,561,983 votes for, 40,324 against.
All proposals passed as detailed in the April 28, 2025 proxy statement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.